8 Apr 2021 17:28
Arix Bioscience PLC (ARIX) Transaction in own shares 08-Apr-2021 / 17:27 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.  Arix Bioscience plc  Transaction in own shares  LONDON, 08 April 2021: Arix Bioscience plc ("Arix" or "the Company"), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that it purchased the following number of its ordinary shares of 0.001 pence each on the London Stock Exchange from Jefferies International Limited as part of a buyback programme announced on 22 March 2021. Â
 Arix intends to retain the purchased shares in treasury. Following settlement of the above purchase, Arix will have 134,628,653 ordinary shares of 0.001 pence each in issue (excluding 981,000 ordinary shares of 0.001 pence each held in treasury). This number represents the total voting rights in Arix and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules. In accordance with Article 5(1)(b) of Regulation (EU) No. 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018), the schedule below contains detailed information of the individual trades made by Jefferies International Limited as part of the buyback programme. [ENDS]  For more information on Arix, please contact:  Arix Bioscience plc Charlotte Parry, Head of Investor Relations +44 (0)20 7290 1072 charlotte@arixbioscience.com   Optimum Strategic Communications Mary Clark, Supriya Mathur, Shabnam Bashir +44 (0)20 3922 1906 optimum.arix@optimumcomms.com   About Arix Bioscience plc Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences. We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com  Â
  |
| ISIN: | GB00BD045071 |
| Category Code: | POS |
| TIDM: | ARIX |
| LEI Code: | 213800OVT3AHQCXNIX43 |
| OAM Categories: | 2.4. Acquisition or disposal of the issuer's own shares |
| Sequence No.: | 97954 |
| EQS News ID: | 1182646 |
| Â | |
| End of Announcement | EQS News Service |
UK Regulatory announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.